David McNally.

David McNally, Ph.D.

Assistant Research Professor

College
Francis College of Engineering
Department
Chemical Engineering
Email
david_mcnally@uml.edu

Research Interests

Intensified methods of viral vector manufacture and development of novel analytical methods for viral vector characterization. Collaborations with industrial and academic partners to further develop these aims, both directly and via leading networks such as the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC).

Education

  • Ph.D., Chemical Engineering), University of Cambridge, Cambridge, United Kingdom, 2013 
    • Thesis Title: Membrane Chromatography: Application in Integrated Viral Vector Manufacture Advisor: Professor Nigel K.H. Slater FREng, FIChemE , Peter Levison. Ph.D.
  • BSc., Biomedical Science (1st Class), University of Sheffield, Sheffield, United Kingdom, 2007

Biosketch

David McNally, Ph.D., primarily researches intensified methods of viral vector manufacture and development of novel analytical methods for viral vector characterization. He has actively engaged in collaborations with industrial and academic partners to further develop these aims, both directly and via leading networks such as the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). David started his career in Manufacturing Operations in Downstream processing and validation of vaccine manufacturing processes. David received his undergraduate degree in Biomedical Sciences from the University of Sheffield and his Ph.D. in Chemical Engineering from the University of Cambridge.

Major Leadership Roles

  • Head, Process Development - VMC MassBiologics, Fall River, Massachusetts - 2019-Present
    • Responsible for leadership of viral vector process development and research into new viral vector manufacturing platforms for MassBiologics’ Vector Manufacturing Center. Simultaneous management of client contract development projects and academic grant funded collaborations. Five Research Associates and two Scientists within direct reporting structure, indirect management of seven additional Research Associates and Scientist for project and grant specific tasks.
  • Senior Scientist, MilliporeSigma, Carlsbad, California - 2017-2019.
    • Responsible for Process development and technical transfer to cGMP manufacture of viral gene therapy vectors and vaccines using both suspension and attachment cell culture methods, including batch and perfusion methodology.
  • Senior Scientist II – Process Development, St Jude Children’s Research Hospital, Memphis, Tennessee - 2015-2017.
  • Senior Scientist I – GMP, St Jude Children’s Research Hospital, Memphis, Tennessee – 2015.
  • Scientist – Validation, Protein Sciences Corporation, Meriden, Connecticut – 2014.
  • Scientist – Manufacturing, Protein Sciences Corporation, Meriden, Connecticut - 2013-2014.

Selected Presentations

  • David McNally, David Darling, Farzin Farzaneh, Peter Levison, Nigel Slater, “Optimised concentration and purification of retroviruses using membrane chromatography”, Journal of Chromatography A, Volume 1340, Pages 24-32 (2014).
  • Rongjun Chen, Najeem Folarin, Vincent H.B. Ho, David McNally, David Darling, Farzin Farzaneh, Nigel K.H. Slater, “Affinity recovery of lentivirus by diaminopelargonic acid mediated desthiobiotin labelling”, Journal of Chromatography B, Volume 878, Issue 22 (2010)
  • Nickolas Darton, David Darling, Matthew Townsend, David McNally, Farzin Farzaneh, Nigel K.H. Slater, “Lentivirus capture directly from cell culture with Q-functionalised microcapillary film chromatography”, Journal of Chromatography A, Volume 1251, Pages 236–239, (2012).

Selected Intellectual Property

  • “Method for Isolating and Purifying Adeno-Associated Virus Particles Using Salt.”, US20180135024A1 (2018).

Selected Contracts, Fellowships, Grants and Sponsored Research

  • Agency Grant Number 70NANB17H002 PC1.0-12 & 36Principal Investigator (PI) Dr, David McNally, Ph.D, “Improved Lentiviral Vector Biomanufacturing for Cell and Gene Therapy Applications”. Investigation of process intensification technologies such as perfusion cell culture to improve the productivity and quality of Lentiviral Gene Therapy Vector manufacturing processes. Total, direct & indirect costs $1,556,104, 2019-2020.
  • Principal Investigator (PI) Dr, David McNally, Ph.D, “Continuous Cell Culture for Viral Vaccines”. Development of a mechanistic model of vaccine production for the development and demonstration of the continuous operation of an upstream cell culture process for the production of a model vaccine. Total, direct & indirect costs $760,242, 2019-2020.